Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[thefamilyman]

Please keep posting your DD. The fact that there are 100s or 1000s of studies that associate NFkB with the pathology of specific diseases should be interesting to the long term investors in STSI.

Once the capabilities of anatabine to address NFkB are well known in the medical research community; how long will it take for the researchers involved in ALL those studies to associate the possibilities presented by anatabine with their previously published work? I think the next few years are going to be very interesting for Star.